Alx Oncology Holdings Inc SEC filings ALXO
Alx Oncology Holdings Inc has 421 filings in SEC EDGAR's recent list, going back to May 5, 2020. Its latest annual report, Form ARS, was filed on Apr 20, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (material agreement, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 20, 2026 | Apr 17, 2026 |
| DEF 14A | Proxy statement | Apr 21, 2025 | Apr 21, 2025 |
| DEFA14A | Additional proxy material | May 2, 2024 | — |
| DEF 14A | Proxy statement | Apr 22, 2024 | Jun 12, 2024 |
| DEF 14A | Proxy statement | Apr 24, 2023 | Jun 16, 2023 |
| DEF 14A | Proxy statement | Apr 22, 2022 | Jun 14, 2022 |
| DEF 14A | Proxy statement | Apr 29, 2021 | Jun 10, 2021 |
Showing 7 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALXO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1810182
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.